Alteogen Inc.
196170
株式のランク
#1836
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters,... ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology; and ALT-LS2, a SC (subcutaneous) formulation of trastuzuamb for the treatment of breast and gastric cancer. The company has a strategic alliance with Kissei Pharmaceutical for the development of ALT-L9, a biosimilar of Eylea (Aflibercept) which is currently under Phase 1 trial; Cristalia for the development of ALT-L2, a biosimilar of Herceptin (Trastuzumab), a monoclonal antibody for the treatment of breast cancer, which is in the Phase II clinical trial; and Biogen Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.
株価
$165.61
時価総額
$11.53B
変化（1日）
4.13%
変化（1年）
-46.48%
国
KR
取引 Alteogen Inc. (196170)
カテゴリー
Healthcare
Alteogen Inc.（196170）の収益
Jun 2026 時点の収益 TTM: $175.65M
Alteogen Inc. の最新の財務報告によると、現在の収益 (TTM) は $175.65M です。2023 年には $74.56M の収益があり、これは 2022 年の $22.83M と比較して 増加 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Alteogen Inc. の収益履歴（2012 ～ 2026）
各年末の収益
| 年 | 収益 | 変化 |
|---|---|---|
| 2026 (TTM) | $175.65M | 151.07% |
| 2024 | $69.96M | -6.17% |
| 2023 | $74.56M | 226.63% |
| 2022 | $22.83M | -29.96% |
| 2021 | $32.59M | -16.60% |
| 2020 | $39.08M | 54.39% |
| 2019 | $25.31M | 105.68% |
| 2018 | $12.31M | 8.35% |
| 2017 | $11.36M | 100.10% |
| 2016 | $5.68M | 41.12% |
| 2015 | $4.02M | -37.51% |
| 2014 | $6.44M | 22.58% |
| 2013 | $5.25M | 41.14% |
| 2012 | $3.72M | 0.00% |
同業他社の収益
| 企業 | 収益 | 収益の差 | 国 |
|---|---|---|---|
| $12.62B | 7,087.26% |
US
|
|
| $2.23B | 1,168.44% |
US
|
|
| $15.74B | 8,863.55% |
AU
|
|
| $6.02B | 3,328.04% |
NL
|
|
| - | - |
CH
|
